DIF-3 是一种具有口服活性的抗癌剂,通过激活 GSK-3β 促进细胞周期蛋白 D1 和 c-Myc 的降解从而降低其表达水平,抑制细胞中 Wnt/β-catenin 信号通路相关蛋白,诱导活性氧 (ROS) 和细胞自噬 (autophagy),在 HT1080 细胞中抑制克氏锥虫生长,并在体外和体内均发挥抗肿瘤作用。
产品编号: MS-J95246 纯度: 99.84% CAS No.: 113411-17-9 分子式: C13H17ClO4 分子量: 272.72
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

DIF-3 是一种具有口服活性的抗癌剂,通过激活 GSK-3β 促进细胞周期蛋白 D1 和 c-Myc 的降解从而降低其表达水平,抑制细胞中 Wnt/β-catenin 信号通路相关蛋白,诱导活性氧 (ROS) 和细胞自噬 (autophagy),在 HT1080 细胞中抑制克氏锥虫生长,并在体外和体内均发挥抗肿瘤作用。

生物实验数据

生物活性 DIF-3 is an orally active anticancer agent that promotes the degradation of cyclin D1 and c-Myc by activating GSK-3β, thereby reducing their expression levels, inhibits Wnt/β-catenin signaling pathway-related proteins in cells, induces reactive oxygen species (ROS) and autophagy, inhibits Trypanosoma cruzi growth in HT1080 cells, and exerts antitumor effects both in vitro and in vivo.
体外研究
(In Vitro)

DIF-3 (10-30 μM, 24-48 h) 以剂量依赖性方式抑制人类结肠癌细胞的增殖。
DIF-3 (30 μM, 24 h) 将人类结肠癌细胞的细胞周期停滞在 G0/G1 期。
DIF-3 (10-30 μM, 1-24 h) 通过激活 GSK-3β 诱导人类结肠癌细胞中细胞周期蛋白 D1 和 c-Myc 的蛋白水解。
DIF-3 (10-30 μM, 1-24 h) 抑制人类结肠癌细胞中的 Wnt/β-catenin 信号通路相关蛋白。
DIF-3 (10 μM,4 h) 抑制溶血磷脂酸 (LPA) 诱导的小鼠骨肉瘤 LM8 细胞迁移。
DIF-3 (20 μM, 0.25-24 h) 抑制 mTOR 信号传导并诱导 K562 CML 细胞自噬。
DIF-3 (20 μM) 诱导 K562 细胞中的线粒体膜电位 (MMP) (0-10 min)、ATP 含量降低 (6 h) 和 ROS 产生 (0-30 min)。
DIF-3 (10 μM, 3 d) 抑制 HT1080 细胞中克氏锥虫的生长,IC50 为 3.95 μM。

Cell Proliferation Assay

Cell Line: HCT-116, DLD-1
Concentration: 10, 20, 30 μM
Incubation Time: 24, 48 h
Result: Strongly inhibited proliferation in a dose-dependent manner in both cell lines.
HCT-116 cells were more sensitive to DIF-3 than DLD-1 cells.

Cell Cycle Analysis

Cell Line: HCT-116, DLD-1
Concentration: 30 μM
Incubation Time: 24 h
Result: Significantly increased the number of cells in G0/G1 phase and decreased those in S phase in both cell lines.
Also significantly increased the number of cells in G2 phase when HCT-116 cells were employed, this effect was not observed by using DLD-1 cells.

Cell Migration Assay

Cell Line: LM8
Concentration: 10 μM
Incubation Time: 4 h
Result: Suppressed LPA-induced cell migration, whereas did not significantly affected cell migration in the absence of LPA.

Cell Autophagy Assay

Cell Line: K562
Concentration: 20 μM
Incubation Time: 0.25, 0.5, 1, 3, 6, 24 h for mTOR study; 6, 16, 36, 48 h for Cathepsin B activity study
Result: Induced the rapid dephosphorylation of mTOR at Ser2481. Inhibited the mTOR pathway and leads to a rapid and robust conversion of LC3-I to LC3-II.
Increased autophagy was accompanied by the late activation of cathepsin B.

Western Blot Analysis

Cell Line: HCT-116
Concentration: 10, 20, 30 μM
Incubation Time: 1, 3, 6, 12, 24 h
Result: Induced a rapid and marked reduction in the amount of cyclin D1 protein and c-Myc protein in a time and dose-dependent manner.
Had no effect on the expression level of β-catenin (30 μM for 24 h).
Reduced the amount of TCF7L2 which increased gradually over time in control cells, in a time and dose-dependent manner.
Reduction of TCF7L2 was associated with the transcriptional inhibition of cyclin D1 mRNA in HCT-116 cells.

Western Blot Analysis

Cell Line: HCT-116
Concentration: 30 μM
Incubation Time: 1 h
Result: Effects could be attenuated by MG132 (MS-L06849) and SB216763 (MS-Y17858), indicating the involvement of GSK-3β in degradation of cyclin D1 and c-Myc.
体内研究
(In Vivo)

DIF-3 (150 mg/kg;口服;每天一次,每周 5 天,持续 4 周) 可抑制 Mutyh-/- 小鼠中氧化应激 (0.2% KBrO3) 诱发的肿瘤。

Animal Model: Mutyh-/- mice (KBrO3 dissolved in water at a concentration of 2 g/L was administered to 4-week-old mice for 12 weeks)
Dosage: 150 mg/kg
Administration: Oral gavage (p.o.); once a day for 5 days/week over 4 weeks
Result: Markedly reduced the number of intestinal tumors, especially the number of large tumors with a diameter of >2.0 mm.
No differences in the appearance, activity, body weight, or blood cell counts.
The numbers of TCF7L2-and cyclin D1-positive nuclei in tumors were significantly decreased.
性状 固体
颜色 White to off-white

化学信息

分子量 272.72
分子式 C13H17ClO4
CAS No. 113411-17-9

储存&溶解度

体内实验配方
10% DMSO+90% Corn Oil: 3.3 mg/mL (12.1 mM), Sonication is recommended.
10% DMSO+90% Saline: < 2.08 mg/mL (7.63 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.08 mg/mL (7.63 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (366.68 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.6668 mL18.3338 mL36.6676 mL91.6691 mL
5 mM0.7334 mL3.6668 mL7.3335 mL18.3338 mL
10 mM0.3667 mL1.8334 mL3.6668 mL9.1669 mL
15 mM0.2445 mL1.2223 mL2.4445 mL6.1113 mL
20 mM0.1833 mL0.9167 mL1.8334 mL4.5835 mL
25 mM0.1467 mL0.7334 mL1.4667 mL3.6668 mL
30 mM0.1222 mL0.6111 mL1.2223 mL3.0556 mL
40 mM0.0917 mL0.4583 mL0.9167 mL2.2917 mL
50 mM0.0733 mL0.3667 mL0.7334 mL1.8334 mL
60 mM0.0611 mL0.3056 mL0.6111 mL1.5278 mL
80 mM0.0458 mL0.2292 mL0.4583 mL1.1459 mL
100 mM0.0367 mL0.1833 mL0.3667 mL0.9167 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础